{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T05:55:46Z","timestamp":1787637346697,"version":"build-2736575974"},"reference-count":96,"publisher":"Bentham Science Publishers Ltd.","issue":"4","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDT"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Neglected tropical diseases (NTDs) are responsible for over 500,000 deaths annually and\nare characterized by multiple disabilities. Leishmaniasis and Chagas diseases are among the most\nsevere NTDs, and are caused by the Leishmania sp and Trypanosoma cruzi, respectively. Glucantime,\npentamidine, and miltefosine are commonly used to treat leishmaniasis, whereas nifurtimox, benznidazole\nare current treatments for Chagas disease. However, these treatments are associated with drug\nresistance and severe side effects. Hence, the development of synthetic products, especially those\ncontaining N0&lt;sub&gt;2&lt;\/sub&gt;, F, or Cl, are known to improve biological activity. The present work summarizes the\ninformation on the antileishmanial and antitrypanosomal activity of nitro-, chloro-, and fluorosynthetic\nderivatives. Scientific publications referring to halogenated derivatives in relation to antileishmanial\nand antitrypanosomal activities were hand-searched in databases such as SciFinder,\nWiley, Science Direct, PubMed, ACS, Springer, Scielo, and so on. According to the literature information,\nmore than 90 compounds were predicted as lead molecules with reference to their IC&lt;sub&gt;50&lt;\/sub&gt;\/EC&lt;sub&gt;50&lt;\/sub&gt;\nvalues in in vitro studies. It is worth mentioning that only active compounds with known cytotoxic\neffects against mammalian cells were considered in the present study. The observed activity was attributed\nto the presence of nitro-, fluoro-, and chloro-groups in the compound backbone. All in all,\nnitro and halogenated derivatives are active antileishmanial and antitrypanosomal compounds and can\nserve as the baseline for the development of new drugs against leishmaniasis and Chagas disease.\nHowever, efforts in in vitro and in vivo toxicity studies of the active synthetic compounds is still\nneeded. Pharmacokinetic studies and the mechanism of action of the promising compounds need to be\nexplored. The use of new catalysts and chemical transformation can afford unexplored halogenated\ncompounds with improved antileishmanial and antitrypanosomal activity.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389450121666201228122239","type":"journal-article","created":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T06:25:06Z","timestamp":1609223106000},"page":"379-398","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The Role of Nitro (NO2-), Chloro (Cl), and Fluoro (F) Substitution in the Design of Antileishmanial and Antichagasic Compounds"],"prefix":"10.2174","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4982-0507","authenticated-orcid":true,"given":"Boniface P.","family":"Kamdem","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Faculty of Pharmaceutical Sciences, University of Sao Paulo, Sao Paulo,Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferreira I.","family":"Elizabeth","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Faculty of Pharmaceutical Sciences, University of Sao Paulo, Sao Paulo,Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"e330","DOI":"10.1016\/S1473-3099(19)30160-4","volume":"19","author":"Chami G.F.","year":"2019","unstructured":"Chami G.F.; Bundy D.A.P.; More medicines alone cannot ensure the treatment of neglected tropical diseases. Lancet Infect Dis 2019,19(9),e330-e336","journal-title":"Lancet Infect Dis"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1001\/jamadermatol.2018.2133","volume":"154","author":"McIlwee B.E.","year":"2018","unstructured":"McIlwee B.E.; Weis S.E.; Hosler G.A.; Incidence of endemic human cutaneous leishmaniasis in the United States. JAMA Dermatol 2018,154(9),1032-1039","journal-title":"JAMA Dermatol"},{"key":"ref=3","year":"2020","unstructured":"The leishmaniases World Health Organization (W.H.O.)2020 https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/leishmaniasis","journal-title":"The leishmaniases"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3389\/fpubh.2019.00166","volume":"7","author":"Lidani K.C.F.","year":"2019","unstructured":"Lidani K.C.F.; Andrade F.A.; Bavia L.; Chagas Disease: From discovery to a worldwide health problem. Front Public Health 2019,7,166","journal-title":"Front Public Health"},{"key":"ref=5","year":"2020","unstructured":"Chagas disease World Health Organization (WHO)2020 https:\/\/www.who.int\/news-room\/facts-in-pictures\/detail\/chagas-disease","journal-title":"Chagas disease"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.2174\/156802611796575894","volume":"11","author":"Wilkinson S.R.","year":"2011","unstructured":"Wilkinson S.R.; Bot C.; Kelly J.M.; Hall B.S.; Trypanocidal activity of nitroaromatic prodrugs: current treatments and future perspectives. Curr Top Med Chem 2011,11(16),2072-2084","journal-title":"Curr Top Med Chem"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"e202","DOI":"10.1093\/cid\/ciw670","volume":"63","author":"Aronson N.","year":"2016","unstructured":"Aronson N.; Herwaldt B.L.; Libman M.; Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis 2016,63(12),e202-e264","journal-title":"Clin Infect Dis"},{"key":"ref=8","doi-asserted-by":"publisher","DOI":"10.1002\/cbdv.202000142","volume":"17","author":"Antol\u00ednez I.V.","year":"2020","unstructured":"Antol\u00ednez I.V.; Barbosa L.C.A.; Borgati T.F.; Tetraoxanes as new agents against Leishmania amazonensis. Chem Biodivers 2020,17(6)","journal-title":"Chem Biodivers"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1021\/acsmedchemlett.9b00566","volume":"11","author":"Pedron J.","year":"2020","unstructured":"Pedron J.; Boudot C.; Brossas J.Y.; New 8-nitroquinolinone derivative displaying submicromolar in vitro activities against both Trypanosoma brucei and cruzi. ACS Med Chem Lett 2020,11(4),464-472","journal-title":"ACS Med Chem Lett"},{"key":"ref=10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005971","volume":"12","author":"Wyllie S.","year":"2016","unstructured":"Wyllie S.; Roberts A.J.; Norval S.; Activation of bicyclic nitro-drugs by a novel nitroreductase (NTR2) in Leishmania. PLoS Pathog 2016,12(11)","journal-title":"PLoS Pathog"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.ejmech.2015.08.042","volume":"103","author":"Papadopoulou M.V.","year":"2015","unstructured":"Papadopoulou M.V.; Bloomer W.D.; Rosenzweig H.S.; O\u2019Shea I.P.; Wilkinson S.R.; Kaiser M.; 3-Nitrotriazole-based piperazides as potent antitrypanosomal agents. Eur J Med Chem 2015,103,325-334","journal-title":"Eur J Med Chem"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1021\/jm5015742","volume":"58","author":"Papadopoulou M.V.","year":"2015","unstructured":"Papadopoulou M.V.; Bloomer W.D.; Lepesheva G.I.; Novel 3-nitrotriazole-based amides and carbinols as bifunctional antichagasic agents. J Med Chem 2015,58(3),1307-1319","journal-title":"J Med Chem"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.bmc.2007.07.031","volume":"16","author":"Gerpe A.","year":"2008","unstructured":"Gerpe A.; Odreman-Nu\u00f1ez I.; Draper P.; Heteroallyl-containing 5-nitrofuranes as new anti-Trypanosoma cruzi agents with a dual mechanism of action. Bioorg Med Chem 2008,16(1),569-577","journal-title":"Bioorg Med Chem"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.bmcl.2008.11.078","volume":"19","author":"Ma X.","year":"2009","unstructured":"Ma X.; Zhou W.; Brun R.; Synthesis, in vitro antitrypanosomal and antibacterial activity of phenoxy, phenylthio or benzyloxy substituted quinolones. Bioorg Med Chem Lett 2009,19(3),986-989","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"7449","DOI":"10.1016\/j.bmc.2009.09.030","volume":"17","author":"Dea-Ayuela M.A.","year":"2009","unstructured":"Dea-Ayuela M.A.; Castillo E.; Gonzalez-Alvarez M.; In vivo and in vitro anti-leishmanial activities of 4-nitro-N-pyrimidin- and N-pyrazin-2-ylbenzenesulfonamides, and N2-(4-nitrophenyl)-N1-propylglycinamide. Bioorg Med Chem 2009,17(21),7449-7456","journal-title":"Bioorg Med Chem"},{"key":"ref=16","author":"Sakib B.","year":"2018","unstructured":"Sakib B.; Simon L.C.; Marleen B.; Leishmaniasis 2018 www.thelancet. com"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.4314\/ahs.v19i1.4","volume":"19","author":"Tabbabi A.","year":"2019","unstructured":"Tabbabi A.; Review of Leishmaniasis in the Middle East and North Africa. Afr Health Sci 2019,19(1),1329-1337","journal-title":"Afr Health Sci"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"961","DOI":"10.3855\/jidc.4310","volume":"8","author":"Elmahallawy E.K.","year":"2014","unstructured":"Elmahallawy E.K.; Sampedro Martinez A.; Rodriguez-Granger J.; Diagnosis of leishmaniasis. J Infect Dev Ctries 2014,8(8),961-972","journal-title":"J Infect Dev Ctries"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0035671","volume":"7","author":"Alvar J.","year":"2012","unstructured":"Alvar J.; V\u00e9lez I.D.; Bern C.; W.H.O. Leishmaniasis Control Team. PLoS One 2012,7(5),1-13","journal-title":"PLoS One"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.apar.2018.11.001","volume":"104","author":"Rostamian M.","year":"2019","unstructured":"Rostamian M.; Niknam H.M.; Leishmania tropica: What we know from its experimental models. Adv Parasitol 2019,104,1-38","journal-title":"Adv Parasitol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1080\/20477724.2016.1232042","volume":"110","author":"Maspi N.","year":"2016","unstructured":"Maspi N.; Abdoli A.; Ghaffarifar F.; Pro- and anti-inflammatory cytokines in cutaneous leishmaniasis: a review. Pathog Glob Health 2016,110(6),247-260","journal-title":"Pathog Glob Health"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.clindermatol.2006.05.008","volume":"25","author":"Bailey M.S.","year":"2007","unstructured":"Bailey M.S.; Lockwood D.N.; Cutaneous leishmaniasis. Clin Dermatol 2007,25(2),203-211","journal-title":"Clin Dermatol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1146\/annurev.micro.55.1.453","volume":"55","author":"Sacks D.","year":"2001","unstructured":"Sacks D.; Kamhawi S.; Molecular aspects of parasite-vector and vector-host interactions in leishmaniasis. Annu Rev Microbiol 2001,55,453-483","journal-title":"Annu Rev Microbiol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/nrmicro2608","volume":"9","author":"Kaye P.","year":"2011","unstructured":"Kaye P.; Scott P.; Leishmaniasis: complexity at the host-pathogen interface. Nat Rev Microbiol 2011,9(8),604-615","journal-title":"Nat Rev Microbiol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nri.2016.72","volume":"16","author":"Scott P.","year":"2016","unstructured":"Scott P.; Novais F.O.; Cutaneous leishmaniasis: immune responses in protection and pathogenesis. Nat Rev Immunol 2016,16(9),581-592","journal-title":"Nat Rev Immunol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1016\/j.vaccine.2019.04.092","volume":"37","author":"Ratnapriya S.","year":"2019","unstructured":"Ratnapriya S.; Keerti, Sahasrabuddhe AA, Dube A. Visceral leishmaniasis: An overview of vaccine adjuvants and their applications. Vaccine 2019,37(27),3505-3519","journal-title":"Vaccine"},{"key":"ref=27","author":"Cox F.E.G.","year":"1993","unstructured":"Cox F.E.G.;  A text book of parasitology 1993","journal-title":"A text book of parasitology"},{"key":"ref=28","author":"Roberts L.S.","year":"2009","unstructured":"Roberts L.S.; Janovy J.; Schmidt G.D.;  Foundations of parasitology 2009","journal-title":"Foundations of parasitology"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1086\/425747","volume":"39","author":"Weina P.J.","year":"2004","unstructured":"Weina P.J.; Neafie R.C.; Wortmann G.; Polhemus M.; Aronson N.E.; Old world leishmaniasis: an emerging infection among deployed US military and civilian workers. Clin Infect Dis 2004,39(11),1674-1680","journal-title":"Clin Infect Dis"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.1128\/JCM.38.10.3768-3773.2000","volume":"38","author":"Ram\u00edrez J.R.","year":"2000","unstructured":"Ram\u00edrez J.R.; Agudelo S.; Muskus C.; Diagnosis of cutaneous leishmaniasis in Colombia: the sampling site within lesions influences the sensitivity of parasitologic diagnosis. J Clin Microbiol 2000,38(10),3768-3773","journal-title":"J Clin Microbiol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1093\/jac\/dkh058","volume":"53","author":"Blum J.","year":"2004","unstructured":"Blum J.; Desjeux P.; Schwartz E.; Beck B.; Hatz C.; Treatment of cutaneous leishmaniasis among travellers. J Antimicrob Chemother 2004,53(2),158-166","journal-title":"J Antimicrob Chemother"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1590\/S0074-02762000000200012","volume":"95","author":"Amaral V.","year":"2000","unstructured":"Amaral V.; Pirmez C.; Gon\u00e7alves A.; Ferreira V.; Grimaldi G.; Cell populations in lesions of cutaneous leishmaniasis of Leishmania (L.) amazonensis- infected rhesus macaques, Macaca mulatta. Mem Inst Oswaldo Cruz 2000,95(2),209-216","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1136\/bmj.329.7470.842","volume":"329","author":"Ahluwalia S.","year":"2004","unstructured":"Ahluwalia S.; Lawn S.D.; Kanagalingam J.; Grant H.; Lockwood D.N.; Mucocutaneous leishmaniasis: an imported infection among travellers to central and South America. BMJ 2004,329(7470),842-844","journal-title":"BMJ"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.actatropica.2004.09.005","volume":"93","author":"Romero G.A.","year":"2005","unstructured":"Romero G.A.; de la Gl\u00f3ria Orge Orge M.; de Farias Guerra M.V.; Paes M.G.; de Oliveira Mac\u00eado V.; de Carvalho E.M.; Antibody response in patients with cutaneous leishmaniasis infected by Leishmania (Viannia) braziliensis or Leishmania (Viannia) guyanensis in Brazil. Acta Trop 2005,93(1),49-56","journal-title":"Acta Trop"},{"key":"ref=35","first-page":"839","author":"Santar\u00e9m N.","year":"2007","unstructured":"Santar\u00e9m N.; Cordeiro da Silva A.;  Diagnosis of visceral leishmaniasisCommunicating current research and educational topics and trends in applied microbiology 2007,839-846","journal-title":"Diagnosis of visceral leishmaniasisCommunicating current research and educational topics and trends in applied microbiology"},{"key":"ref=36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMicm1908092","author":"Knapp A.P.","unstructured":"Knapp A.P.; Alpern J.D.;  Cutaneous leishmaniasis Images in clinical\nmedicine N Engl J Med 2020; 382: 1","journal-title":"Cutaneous leishmaniasis Images in clinical\nmedicine N Engl J Med 2020; 382: 1"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.3390\/ijerph7124267","volume":"7","author":"Sundar S.","year":"2010","unstructured":"Sundar S.; Chakravarty J.; Antimony toxicity. Int J Environ Res Public Health 2010,7(12),4267-4277","journal-title":"Int J Environ Res Public Health"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1086\/318121","volume":"31","author":"Sundar S.","year":"2000","unstructured":"Sundar S.; More D.K.; Singh M.K.; Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 2000,31(4),1104-1107","journal-title":"Clin Infect Dis"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/0166-6851(94)90057-4","volume":"63","author":"Souza A.E.","year":"1994","unstructured":"Souza A.E.; Bates P.A.; Coombs G.H.; Mottram J.C.; Null mutants for the lmcpa cysteine proteinase gene in Leishmania mexicana. Mol Biochem Parasitol 1994,63(2),213-220","journal-title":"Mol Biochem Parasitol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"18575","DOI":"10.1074\/jbc.M400652200","volume":"279","author":"El Fadili A.","year":"2004","unstructured":"El Fadili A.; K\u00fcndig C.; Roy G.; Ouellette M.; Inactivation of the Leishmania tarentolae pterin transporter (BT1) and reductase (PTR1) genes leads to viable parasites with changes in folate metabolism and hypersensitivity to the antifolate methotrexate. J Biol Chem 2004,279(18),18575-18582","journal-title":"J Biol Chem"},{"key":"ref=41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0004322","volume":"10","author":"Fiuza J.A.","year":"2016","unstructured":"Fiuza J.A.; Dey R.; Davenport D.; Intradermal immunization of Leishmania donovani centrin knock-out parasites in combination with salivary protein LJM19 from sand fly vector induces a durable protective immune response in hamsters. PLoS Negl Trop Dis 2016,10(1)","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0264-410X(01)00322-X","volume":"20","author":"Ghosh A.","year":"2001","unstructured":"Ghosh A.; Zhang W.W.; Matlashewski G.; Immunization with A2 protein results in a mixed Th1\/Th2 and a humoral response which protects mice against Leishmania donovani infections. Vaccine 2001,20(1-2),59-66","journal-title":"Vaccine"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1016\/j.vaccine.2008.01.042","volume":"26","author":"Carrillo E.","year":"2008","unstructured":"Carrillo E.; Crusat M.; Nieto J.; Immunogenicity of HSP-70, KMP-11 and PFR-2 leishmanial antigens in the experimental model of canine visceral leishmaniasis. Vaccine 2008,26(15),1902-1911","journal-title":"Vaccine"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"7064","DOI":"10.4049\/jimmunol.165.12.7064","volume":"165","author":"St\u00e4ger S.","year":"2000","unstructured":"St\u00e4ger S.; Smith D.F.; Kaye P.M.; Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. J Immunol 2000,165(12),7064-7071","journal-title":"J Immunol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"7450","DOI":"10.1016\/j.vaccine.2007.08.001","volume":"25","author":"Goto Y.","year":"2007","unstructured":"Goto Y.; Bogatzki L.Y.; Bertholet S.; Coler R.N.; Reed S.G.; Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant. Vaccine 2007,25(42),7450-7458","journal-title":"Vaccine"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1086\/430348","volume":"191","author":"Tewary P.","year":"2005","unstructured":"Tewary P.; Jain M.; Sahani M.H.; Saxena S.; Madhubala R.; A heterologous prime-boost vaccination regimen using ORFF DNA and recombinant ORFF protein confers protective immunity against experimental visceral leishmaniasis. J Infect Dis 2005,191(12),2130-2137","journal-title":"J Infect Dis"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00436-005-0008-8","volume":"98","author":"Marques-da-Silva E.A.","year":"2005","unstructured":"Marques-da-Silva E.A.; Coelho E.A.F.; Gomes D.C.O.; Intramuscular immunization with p36(LACK) DNA vaccine induces IFN-gamma production but does not protect BALB\/c mice against Leishmania chagasi intravenous challenge. Parasitol Res 2005,98(1),67-74","journal-title":"Parasitol Res"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"4863","DOI":"10.1016\/j.vaccine.2006.03.005","volume":"24","author":"Gamboa-Le\u00f3n R.","year":"2006","unstructured":"Gamboa-Le\u00f3n R.; Paraguai de Souza E.; Borja-Cabrera G.P.; Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine of Leishmania donovani. Vaccine 2006,24(22),4863-4873","journal-title":"Vaccine"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"7719","DOI":"10.4049\/jimmunol.0900132","volume":"183","author":"Sharma A.","year":"2009","unstructured":"Sharma A.; Madhubala R.; Ubiquitin conjugation of open reading frame F DNA vaccine leads to enhanced cell-mediated immune response and induces protection against both antimony-susceptible and -resistant strains of Leishmania donovani. J Immunol 2009,183(12),7719-7731","journal-title":"J Immunol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.1016\/j.vaccine.2005.02.009","volume":"23","author":"Rafati S.","year":"2005","unstructured":"Rafati S.; Nakhaee A.; Taheri T.; Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum. Vaccine 2005,23(28),3716-3725","journal-title":"Vaccine"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1016\/j.vaccine.2013.02.025","volume":"31","author":"Guha R.","year":"2013","unstructured":"Guha R.; Das S.; Ghosh J.; Heterologous priming-boosting with DNA and vaccinia virus expressing kinetoplastid membrane protein-11 induces potent cellular immune response and confers protection against infection with antimony resistant and sensitive strains of Leishmania (Leishmania) donovani. Vaccine 2013,31(15),1905-1915","journal-title":"Vaccine"},{"key":"ref=52","author":"Silva-dos-Santos D.","year":"2017","unstructured":"Silva-dos-Santos D.; Barreto-de-Albuquerque J.; Guerra B.; Unraveling Chagas disease transmission through the oral route: Gateways to Trypanosoma cruzi infection and target tissues. PLoS Negl Trop Dis 2017","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1550-7408.1980.tb04228.x","volume":"27","author":"Levine N.D.","year":"1980","unstructured":"Levine N.D.; Corliss J.O.; Cox F.E.; A newly revised classification of the protozoa. J Protozool 1980,27(1),37-58","journal-title":"J Protozool"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/j.1365-2249.2006.03118.x","volume":"145","author":"Lieke T.","year":"2006","unstructured":"Lieke T.; Steeg C.; Graefe S.E.B.; Fleischer B.; Jacobs T.; Interaction of natural killer cells with Trypanosoma cruzi-infected fibroblasts. Clin Exp Immunol 2006,145(2),357-364","journal-title":"Clin Exp Immunol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/S0140-6736(10)60061-X","volume":"375","author":"Rassi A.","year":"2010","unstructured":"Rassi A.; Rassi A.; Marin-Neto J.A.; Chagas disease. Lancet 2010,375(9723),1388-1402","journal-title":"Lancet"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"11292","DOI":"10.1038\/s41598-018-29564-7","volume":"8","author":"Lewis M.D.","year":"2018","unstructured":"Lewis M.D.; Francisco A.F.; Jayawardhana S.; Langston H.; Taylor M.C.; Kelly J.M.; Imaging the development of chronic Chagas disease after oral transmission. Sci Rep 2018,8(1),11292","journal-title":"Sci Rep"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1590\/S0074-02762007000900018","volume":"102","author":"Coura J.R.","year":"2007","unstructured":"Coura J.R.; Chagas disease: what is known and what is needed--a background article. Mem Inst Oswaldo Cruz 2007,102(Suppl. 1),113-122","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1590\/0074-0276140362","volume":"110","author":"Coura J.R.","year":"2015","unstructured":"Coura J.R.; The main sceneries of Chagas disease transmission. The vectors, blood and oral transmissions--a comprehensive review. Mem Inst Oswaldo Cruz 2015,110(3),277-282","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/(SICI)1098-2825(1996)10:6<407:AID-JCLA16>3.0.CO;2-0","volume":"10","author":"Umezawa E.S.","year":"1996","unstructured":"Umezawa E.S.; Shikanai-Yasuda M.A.; Stolf A.M.S.; Changes in isotype composition and antigen recognition of anti-Trypanosoma cruzi antibodies from acute to chronic Chagas disease. J Clin Lab Anal 1996,10(6),407-413","journal-title":"J Clin Lab Anal"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/B978-0-12-801029-7.00030-7","author":"Luquetti A.O.","year":"2017","unstructured":"Luquetti A.O.; Schmu\u00f1is G.A.;  Diagnosis of Trypanosoma cruzi infection American trypanosomiasis chagas disease 2017,687-730","journal-title":"Diagnosis of Trypanosoma cruzi infection American trypanosomiasis chagas disease"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1001\/jama.298.18.2171","volume":"298","author":"Bern C.","year":"2007","unstructured":"Bern C.; Montgomery S.P.; Herwaldt B.L.; Evaluation and treatment of chagas disease in the United States: a systematic review. JAMA 2007,298(18),2171-2181","journal-title":"JAMA"},{"key":"ref=62","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000931","volume":"5","author":"Schijman A.G.","year":"2011","unstructured":"Schijman A.G.; Bisio M.; Orellana L.; International study to evaluate PCR methods for detection of Trypanosoma cruzi DNA in blood samples from Chagas disease patients. PLoS Negl Trop Dis 2011,5(1)","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=63","author":"Brener Z.","unstructured":"Brener Z.; Terap\u00eautica experimental na doen\u00e7a de Chagas.MB-N,\nZ Brener, Z Andrade, editors Trypanosoma cruzi e Doen\u00e7a de\nChagas, 2nd edition Rio de Janeiro: Guanabara Koogan 2000; pp\n379-88","journal-title":"Guanabara Koogan 2000; pp\n379-88"},{"key":"ref=64","author":"Apt W.","year":"2017","unstructured":"Apt W.;  Treatment of Chagas disease American Trypanosomiasis Chagas Disease: One Hundred Years of Research 2017","journal-title":"Treatment of Chagas disease American Trypanosomiasis Chagas Disease: One Hundred Years of Research"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1590\/S0037-86822007000100001","volume":"40","author":"Fabbro D.L.","year":"2007","unstructured":"Fabbro D.L.; Streiger M.L.; Arias E.D.; Bizai M.L.; del Barco M.; Amicone N.A.; Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evolution. Rev Soc Bras Med Trop 2007,40(1),1-10","journal-title":"Rev Soc Bras Med Trop"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ahj.2008.04.001","volume":"156","author":"Marin-Neto J.A.","year":"2008","unstructured":"Marin-Neto J.A.; Rassi A.; Morillo C.A.; Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas\u2019 cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). Am Heart J BENEFIT Investigators2008,156(1),37-43","journal-title":"Am Heart J"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1056\/NEJMoa1507574","volume":"373","author":"Morillo C.A.","year":"2015","unstructured":"Morillo C.A.; Marin-Neto J.A.; Avezum A.; Randomized Trial of Benznidazole for Chronic Chagas\u2019 Cardiomyopathy. N Engl J Med BENEFIT Investigators2015,373(14),1295-1306","journal-title":"N Engl J Med"},{"key":"ref=68","year":"2019","unstructured":"The BENDITA study: A Phase II Study to Assess Safety,\nTolerability, and Efficacy of Different Benznidazole Regimens,\nAlone and in Combination with Fosravuconazole. Drugs for Neglected\nDiseases Initiative (DNDi) DNDi2019 https:\/\/www.dndi.org\/wp-content\/uploads\/2019\/03\/2page_BenditatStudyOverview_ENG.pdf"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s40249-015-0092-7","volume":"4","author":"Liu Q.","year":"2015","unstructured":"Liu Q.; Zhou X-N.; Preventing the transmission of American trypanosomiasis and its spread into non-endemic countries. Infect Dis Poverty 2015,4,60","journal-title":"Infect Dis Poverty"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.exppara.2011.01.009","volume":"127","author":"Estevez Y.","year":"2011","unstructured":"Estevez Y.; Quiliano M.; Burguete A.; Trypanocidal properties, structure-activity relationship and computational studies of quinoxaline 1,4-di-N-oxide derivatives. Exp Parasitol 2011,127(4),745-751","journal-title":"Exp Parasitol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1002\/jps.2600690818","volume":"69","author":"Burghard H.","year":"1980","unstructured":"Burghard H.; DeWitt Blanton C.; 4,5-disubstituted primaquine analogs as potential antiprotozoan agents. J Pharm Sci 1980,69(8),933-936","journal-title":"J Pharm Sci"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1007\/s00436-009-1557-z","volume":"105","author":"Singh N.","year":"2009","unstructured":"Singh N.; Kaur J.; Kumar P.; An orally effective dihydropyrimidone (DHPM) analogue induces apoptosis-like cell death in clinical isolates of Leishmania donovani overexpressing pteridine reductase 1. Parasitol Res 2009,105(5),1317-1325","journal-title":"Parasitol Res"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1021\/jm9013086","volume":"53","author":"Yang M.","year":"2010","unstructured":"Yang M.; Arai C.; Bakar Md A.; Fluorinated rhodacyanine (SJL-01) possessing high efficacy for visceral leishmaniasis (VL). J Med Chem 2010,53(1),368-373","journal-title":"J Med Chem"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1016\/j.bmc.2017.02.016","volume":"25","author":"Tran H-A.","year":"2017","unstructured":"Tran H-A.; Zheng Z.; Wen X.; Synthesis and activity of nucleoside-based antiprotozoan compounds. Bioorg Med Chem 2017,25(7),2091-2104","journal-title":"Bioorg Med Chem"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.ejmech.2014.07.038","volume":"84","author":"Oh S.","year":"2014","unstructured":"Oh S.; Kim S.; Kong S.; Synthesis and biological evaluation of 2,3-dihydroimidazo[1,2-a]benzimidazole derivatives against Leishmania donovani and Trypanosoma cruzi. Eur J Med Chem 2014,84,395-403","journal-title":"Eur J Med Chem"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.parint.2012.05.015","volume":"61","author":"Bilbao-Ramos P.","year":"2012","unstructured":"Bilbao-Ramos P.; Galiana-Rosell\u00f3 C.; Dea-Ayuela M.A.; Nuclease activity and ultrastructural effects of new sulfonamides with anti-leishmanial and trypanocidal activities. Parasitol Int 2012,61(4),604-613","journal-title":"Parasitol Int"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"571","DOI":"10.4155\/fmc-2019-0201","volume":"12","author":"Andrade M.M.S.","year":"2020","unstructured":"Andrade M.M.S.; Martins L.C.; Marques G.V.L.; Synthesis of quinoline derivatives as potential cysteine protease inhibitors. Future Med Chem 2020,12(7),571-581","journal-title":"Future Med Chem"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"8087","DOI":"10.1021\/jm050819t","volume":"48","author":"Parveen S.","year":"2005","unstructured":"Parveen S.; Khan M.O.F.; Austin S.E.; Antitrypanosomal, antileishmanial, and antimalarial activities of quaternary arylalkylammonium 2-amino-4-chlorophenyl phenyl sulfides, a new class of trypanothione reductase inhibitor, and of N-acyl derivatives of 2-amino-4-chlorophenyl phenyl sulfide. J Med Chem 2005,48(25),8087-8097","journal-title":"J Med Chem"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ejmech.2008.04.014","volume":"44","author":"Palit P.","year":"2009","unstructured":"Palit P.; Paira P.; Hazra A.; Phase transfer catalyzed synthesis of bis-quinolines: antileishmanial activity in experimental visceral leishmaniasis and in vitro antibacterial evaluation. Eur J Med Chem 2009,44(2),845-853","journal-title":"Eur J Med Chem"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.bioorg.2018.11.037","volume":"84","author":"Ashok P.","year":"2019","unstructured":"Ashok P.; Chander S.; Smith T.K.; Prakash Singh R.; Jha P.N.; Sankaranarayanan M.; Biological evaluation and structure activity relationship of 9-methyl-1-phenyl-9H-pyrido[3,4-b]indole derivatives as anti-leishmanial agents. Bioorg Chem 2019,84,98-105","journal-title":"Bioorg Chem"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"8186","DOI":"10.1016\/j.bmc.2009.10.030","volume":"17","author":"Rodr\u00edguez J.","year":"2009","unstructured":"Rodr\u00edguez J.; Ar\u00e1n V.J.; Boiani L.; New potent 5-nitroindazole derivatives as inhibitors of Trypanosoma cruzi growth: synthesis, biological evaluation, and mechanism of action studies. Bioorg Med Chem 2009,17(24),8186-8196","journal-title":"Bioorg Med Chem"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"7500","DOI":"10.1016\/j.bmc.2009.09.013","volume":"17","author":"Gerpe A.","year":"2009","unstructured":"Gerpe A.; Alvarez G.; Ben\u00edtez D.; 5-Nitrofuranes and 5-nitrothiophenes with anti-Trypanosoma cruzi activity and ability to accumulate squalene. Bioorg Med Chem 2009,17(21),7500-7509","journal-title":"Bioorg Med Chem"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"6815","DOI":"10.1016\/j.bmc.2015.10.008","volume":"23","author":"de Andrade P.","year":"2015","unstructured":"de Andrade P.; Galo O.A.; Carvalho M.R.; 1,2,3-Triazole-based analogue of benznidazole displays remarkable activity against Trypanosoma cruzi. Bioorg Med Chem 2015,23(21),6815-6826","journal-title":"Bioorg Med Chem"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"4779","DOI":"10.1016\/j.bmc.2003.07.004","volume":"11","author":"Chung M-C.","year":"2003","unstructured":"Chung M-C.; G\u00fcido R.V.C.; Martinelli T.F.; Synthesis and in vitro evaluation of potential antichagasic hydroxymethylnitrofurazone (NFOH-121): a new nitrofurazone prodrug. Bioorg Med Chem 2003,11(22),4779-4783","journal-title":"Bioorg Med Chem"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/molecules21101342","volume":"21","author":"Elias P.R.","year":"2016","unstructured":"Elias P.R.; Coelho G.S.; Xavier V.F.; Synthesis of xylitan derivatives and preliminary evaluation of in vitro trypanocidal activity. Molecules 2016,21(10),1-13","journal-title":"Molecules"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"6818","DOI":"10.1016\/j.bmc.2011.09.037","volume":"19","author":"Caputto M.E.","year":"2011","unstructured":"Caputto M.E.; Fabian L.E.; Ben\u00edtez D.; Thiosemicarbazones derived from 1-indanones as new anti-Trypanosoma cruzi agents. Bioorg Med Chem 2011,19(22),6818-6826","journal-title":"Bioorg Med Chem"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ejmech.2013.04.065","volume":"66","author":"Torres E.","year":"2013","unstructured":"Torres E.; Moreno-Viguri E.; Galiano S.; Novel quinoxaline 1,4-di-N-oxide derivatives as new potential antichagasic agents. Eur J Med Chem 2013,66,324-334","journal-title":"Eur J Med Chem"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jfluchem.2018.08.004","volume":"215","author":"Salsia F.","year":"2018","unstructured":"Salsia F.; Portapilla G.B.; Schutjajew K.; Carneiro Z.A.; Hagenbach A.; de Albuquerque S.; Maia, P.I.-da-S.; Abram, U. Thiosemicarbazones and thiadiazines derived from fluorinated benzoylthioureas: Synthesis, crystal structure and anti-Trypanosoma cruzi activity. J Fluor Sci 2018,215,52-61","journal-title":"J Fluor Sci"},{"key":"ref=89","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2019.126779","volume":"30","author":"Koovits P.J.","year":"2020","unstructured":"Koovits P.J.; Dessoy M.A.; Matheeussen A.; Structure-activity relationship of 4-azaindole-2-piperidine derivatives as agents against Trypanosoma cruzi. Bioorg Med Chem Lett 2020,30(1)","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=90","author":"Muscia G.C.","year":"2019","unstructured":"Muscia G.C.; Pacheco F.J.R.; Asis S.E.; Buldain G.Y.; Frank F.M.; Hit-to-lead optimization of novel 2-alkylaminomethylquinoline derivatives as anti-chagas agents. Eur J Med Chem 2019","journal-title":"Eur J Med Chem"},{"key":"ref=91","author":"Olmo F.","year":"2015","unstructured":"Olmo F.; G\u00f3mez-Contreras F.; Navarro P.; Synthesis and evaluation of in vitro and in vivo trypanocidal properties of a new imidazole-containing nitrophthalazine derivative. Eur J Med Chem 2015","journal-title":"Eur J Med Chem"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.actatropica.2011.12.009","volume":"122","author":"D\u00edaz-Chiguer D.L.","year":"2012","unstructured":"D\u00edaz-Chiguer D.L.; M\u00e1rquez-Navarro A.; Nogueda-Torres B.; In vitro and in vivo trypanocidal activity of some benzimidazole derivatives against two strains of Trypanosoma cruzi. Acta Trop 2012,122(1),108-112","journal-title":"Acta Trop"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1002\/ptr.6383","volume":"33","author":"Boniface P.K.","year":"2019","unstructured":"Boniface P.K.; Ferreira E.I.; Flavonoids as efficient scaffolds: Recent trends for malaria, leishmaniasis, Chagas disease, and dengue. Phytother Res [a2019,33(10),2473-2517","journal-title":"Phytother Res"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.2174\/1389450120666190618114857","volume":"20","author":"Boniface P.K.","year":"2019","unstructured":"Boniface P.K.; Elizabeth F.I.; Flavonoid-derived privileged scaffolds in anti-trypanosoma brucei drug discovery. Curr Drug Targets [b2019,20(12),1295-1314","journal-title":"Curr Drug Targets"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0378-8741(01)00346-4","volume":"78","author":"Weniger B.","year":"2001","unstructured":"Weniger B.; Robledo S.; Arango G.J.; Antiprotozoal activities of Colombian plants. J Ethnopharmacol 2001,78(2-3),193-200","journal-title":"J Ethnopharmacol"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1017\/S003118201300142X","volume":"141","author":"Don R.","year":"2014","unstructured":"Don R.; Ioset J.R.; Screening strategies to identify new chemical diversity for drug development to treat kinetoplastid infections. Parasitology 2014,141(1),140-146","journal-title":"Parasitology"}],"container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389450121666201228122239","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/189514\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389450121666201228122239","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T06:02:51Z","timestamp":1660716171000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/189514\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":96,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389450121666201228122239","relation":{},"ISSN":["1389-4501"],"issn-type":[{"value":"1389-4501","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-06-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-22","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}